Login to myESAIC Membership


The ESAIC is dedicated to supporting professionals in anaesthesiology and intensive care by serving as the hub for development and dissemination of valuable educational, scientific, research, and networking resources.



The ESAIC hosts the Euroanaesthesia and Focus Meeting congresses that serve as platforms for cutting-edge science and innovation in the field. These events bring together experts, foster networking, and facilitate knowledge exchange in anaesthesiology, intensive care, pain management, and perioperative medicine. Euroanaesthesia is one of the world’s largest and most influential scientific congresses for anaesthesia professionals. Held annually throughout Europe, our congress is a contemporary event geared towards education, knowledge exchange and innovation in anaesthesia, intensive care, pain and perioperative medicine, as well as a platform for immense international visibility for scientific research.


Professional Growth

The ESAIC's mission is to foster and provide exceptional training and educational opportunities. The ESAIC ensures the provision of robust and standardised examination and certification systems to support the professional development of anaesthesiologists and to ensure outstanding future doctors in the field of anaesthesiology and intensive care.



The ESAIC aims to advance patient outcomes and contribute to the progress of anaesthesiology and intensive care evidence-based practice through research. The ESAIC Clinical Trial Network (CTN), the Academic Contract Research Organisation (A-CRO), the Research Groups and Grants all contribute to the knowledge and clinical advances in the peri-operative setting.

Learn more about the ESAIC Clinical Trial Network (CTN) and the associated studies.


EU Projects

The ESAIC is actively involved as a consortium member in numerous EU funded projects. Together with healthcare leaders and practitioners, the ESAIC's involvement as an EU project partner is another way that it is improving patient outcomes and ensuring the best care for every patient.


Patient Safety

The ESAIC aims to promote the professional role of anaesthesiologists and intensive care physicians and enhance perioperative patient outcomes by focusing on quality of care and patient safety strategies. The Society is committed to implementing the Helsinki Declaration and leading patient safety projects.



To ESAIC is committed to implementing the Glasgow Declaration and drive initiatives towards greater environmental sustainability across anaesthesiology and intensive care in Europe.



The ESAIC works in collaboration with industry, national societies, and specialist societies to promote advancements in anaesthesia and intensive care. The Industry Partnership offers visibility and engagement opportunities for industry participants with ESAIC members, facilitating understanding of specific needs in anaesthesiology and in intensive care. This partnership provides resources for education and avenues for collaborative projects enhancing science, education, and patient safety. The Specialist Societies contribute to high-quality educational opportunities for European anaesthesiologists and intensivists, fostering discussion and sharing, while the National Societies, through NASC, maintain standards, promote events and courses, and facilitate connections. All partnerships collectively drive dialogue, learning, and growth in the anaesthesiology and intensive care sector.



Guidelines play a crucial role in delivering evidence-based recommendations to healthcare professionals. Within the fields of anaesthesia and intensive care, guidelines are instrumental in standardizing clinical practices and enhancing patient outcomes. For many years, the ESAIC has served as a pivotal platform for facilitating continuous advancements, improving care standards and harmonising clinical management practices across Europe.



With over 40 years of publication history, the EJA (European Journal of Anaesthesiology) has established itself as a highly respected and influential journal in its field. It covers a wide range of topics related to anaesthesiology and intensive care medicine, including perioperative medicine, pain management, critical care, resuscitation, and patient safety.



Becoming a member of ESAIC implies becoming a part of a vibrant community of nearly 8,000 professionals who exchange best practices and stay updated on the latest developments in anaesthesiology, intensive care and perioperative medicine. ESAIC membership equips you with the tools and resources necessary to enhance your daily professional routine, nurture your career growth, and play an active role in advancing anaesthesiology, intensive care and perioperative medicine.

Membership opportunities
at the ESAIC

Newsletter 2021

Newsletter August 2021: Those who are said to be dead live longer – No obituary yet for succinylcholine

Peter Biro

I have to confess that I am a person prone to nostalgic feelings, which certainly apply also for my professional life. However, those warm remembrances that come over me when thinking on the meanwhile rarely used succinylcholine, may have definitely a justifiable reason in some of the unique features of this drug. First, let’s see how this disgraceful abandonment of one of the most widely used anaesthetics came about.

Succinylcholine found its way into clinical use in 1951 under the trade name Lysthenon. Particularly pleasing was its rapid onset of action of less than 1 minute, which reduced the vulnerable phase of unsecured airway in unconsciousness to a tolerable level, until a blocked tracheal tube was in place. This outstanding property of the substance is actually unmatched to this day, even though higher doses of rocuronium are often viewed as an acceptable substitute. I too agree with this view, albeit with few exceptions, especially when things have to be done very quickly. This is the case with a high intestinal obstruction or in caesarean section, if the latter exceptionally is to be carried out under general anaesthesia. The relatively short duration of action of the drug and the absence of permeability through the placenta is also a welcome effect in this context too.

On the other hand, one has to admit that succinylcholine does have some unsightly pharmacodynamic properties, above all the muscular fasciculation, which can have painful after-effects, and on top of may lead to the release of potassium. The inherent destabilizing effect on the integrity of cell membranes, especially in burn patients, and the triggering of malignant hyperthermia have also contributed to its bad reputation. Besides, it also is not advisable to use succinylcholine in patients with muscle disorders, especially those with myodystrophy or myotonia, as well as in patients with elevated intraocular pressure. In this context, the also occasionally occurring arrhythmogenic side effects can already be regarded as venial sins.

A somewhat exaggerated horrific vision that was widely circulated even at the high times of succinylcholine use between the 1960s and 1980s was the occurrence of a phase II block, also known as a dual block. This must have been a rare sighting. I never have encountered it, although I occasionally even used a continuous succinylcholine drip for the maintenance of a neuromuscular block. This phenomenon is due to a conversion of the depolarizing into a non-depolarizing and longer-lasting mode of action on the site of acetylcholine receptors by accumulating metabolites, which may occur if a relatively high dose of the drug has been administered. To be more precise, before shorter-acting neuro-muscular blockers such as atracurium, vecuronium and mivacurium became available, we urgently needed a feasible blocking technique for short interventions with a deep neuromuscular block (e.g. for microlaryngoscopic surgery on the larynx). For this purpose, we slowly infused a solution of 500 mg succinylcholine in 500 ml methylene blue-coloured glucose 5% drip, whereby the infusion rate was adjusted on experience, gut feeling, and some kind of visual inspection. Today something like that would be a free pass to the dock with the public prosecutor – at that time it was standard and practically always worked well. However, it was probably only a matter of time before we would have encountered a patient with atypical cholinesterase. We knew there was such a thing and we were prepared to ventilate an affected person under sedation until he/she could be woken up and sufficiently breathe spontaneously.

Nowadays, with the availability of sugammadex, a short-term, deep relaxation is no longer a technical or medical problem – at best an economic one. With rocuronium and the revered reversal agent we can provide a custom-made block level for any duration of anaesthesia, provided we have the necessary monitoring. But there is one specific application of succinylcholine that is unmatched and has to be mentioned here because it is quite astonishing: succinylcholine is the anaesthetic drug, which has saved most lives! This statement may seem surprising, but it is immediately understandable when you consider that it is the best method to overcome a life-threatening laryngospasm within a few seconds. This can easily be achieved with a bolus dose of 20 to 25 mg, which immediately leads to the relaxation of the vocal cord apparatus without impairing spontaneous breathing. Attempts of forced pressure ventilation with pure oxygen, which is recommended for this, is often not effective in time, can lead to stomach distension or even rupture and, on top of that, does not prevent the phenomenon from recurring. No one who, like me, has experienced the quick, immediate solution to the crisis will allow their succinylcholine to be taken away. In any case, I will definitely not have my 100 mg ampoule of succinylcholine removed from my emergency medication box.



  1. Durant NN, Katz RL Suxamethonium. Br J Anaesth 1982; 54: 195-208
  2. Cook D. Ryan MD.Can Succinylcholine be abandoned? Anesth Analg 2000; 90: S24-S28
  3. Bui DD, Asher SR. Break the spasm with succinylcholine, but risk intraoperative awareness with undiagnosed pseudocholinesterase deficiency. Case Rep Anesthesiol 2020: 8874617. doi: 10.1155/2020/8874617. eCollection 202


Read our Monthly newsletter

Read More of our special newsletter covering our virtual congress 2020.

Visit our COVID-19 Resource Hub for other news and resources.